What drove the surge in 9939.HK stock today?

The surge followed heavy trading volume of **16,164,500.00** shares and speculative interest around biotech catalysts; no single confirmed corporate release tied to the move was public at close. Market coverage and peer volatility likely amplified the move.

How does Meyka AI rate 9939.HK stock?

Meyka AI rates 9939.HK with a score out of 100: **62.97** (Grade B) with a suggestion to HOLD, factoring in benchmarks, sector and company metrics. Grades are informational, not advice.

What are the near-term price forecasts for 9939.HK stock?

Meyka AI's forecast model projects monthly **HKD 2.79** and quarterly **HKD 3.03**, both below the current **HKD 4.05**, implying downside risks. Forecasts are model-based projections and not guarantees.

Should I trade 9939.HK stock after the high-volume move?

High volume creates short-term opportunity and higher volatility; with negative EPS **-0.43** and tight liquidity, active traders can trade intraday with strict stops while long-term investors should await clearer clinical or funding signals.

HK Stocks

9939.HK Kintor +39% on heavy volume, HKSE closed 10 Mar 2026: watch catalysts

ByHuzaifa Zahoor March 10, 2026March 10, 2026

We saw 9939.HK stock surge to HKD 4.05 on 10 Mar 2026 as trading closed, marking a +39.18% move on 16,164,500.00 shares—more than six times average volume. The market-closed rally on the HKSE makes Kintor Pharmaceutical Limited (9939.HK) a clear high-volume mover in Hong Kong healthcare today. We assess the drivers, valuation, technicals and risks to explain why liquidity spiked and what traders may watch next.